How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/haemophilus-influenzae-bronchitis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Haemophilus Influenzae Bronchitis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Haemophilus Influenzae Bronchitis (disease) competitive landscape: 9 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

9 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Haemophilus Influenzae Bronchitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
ALATROFLOXACIN	ALATROFLOXACIN	Pfizer	alatrofloxacin		1997-01-01
Tomefloxacin	GREPAFLOXACIN	Otsuka	grepafloxacin	Potassium voltage-gated channel subfamily H member 2	1997-01-01
Levaquin	levofloxacin	Generic (originally Daiichi Sankyo/J&J)	Fluoroquinolone Antibacterial [EPC]	CAAX prenyl protease 2, Multidrug and toxin extrusion protein 1, Potassium voltage-gated channel subfamily H member 2	1996-12-20
Biaxin	clarithromycin	Generic (originally Abbott/AbbVie)	Macrolide Antimicrobial [EPC]	Potassium voltage-gated channel subfamily H member 2	1991-10-31
Cefzil	cefprozil	Teva Pharmaceuticals USA	Cephalosporin Antibacterial [EPC]		1991-01-01
Ceftin	CEFUROXIME AXETIL	GSK	Cephalosporin Antibacterial		1987-01-01
Azactam	AZTREONAM	Bristol-Myers Squibb	Monobactam Antibacterial [EPC]		1986-01-01
Zinacef	CEFUROXIME	GSK	Cephalosporin Antibacterial	Carbonic anhydrase 2	1983-01-01
Ofloxacine	Ofloxacine	Assistance Publique - Hôpitaux de Paris		Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 7 drugs in Haemophilus Influenzae Bronchitis
GSK · 2 drugs in Haemophilus Influenzae Bronchitis
Bristol-Myers Squibb · 1 drug in Haemophilus Influenzae Bronchitis
Generic (originally Abbott/AbbVie) · 1 drug in Haemophilus Influenzae Bronchitis
Generic (originally Daiichi Sankyo/J&J) · 1 drug in Haemophilus Influenzae Bronchitis
Otsuka · 1 drug in Haemophilus Influenzae Bronchitis
Pfizer · 1 drug in Haemophilus Influenzae Bronchitis
Teva Pharmaceuticals USA · 1 drug in Haemophilus Influenzae Bronchitis
Assistance Publique - Hôpitaux de Paris · 1 drug in Haemophilus Influenzae Bronchitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Haemophilus Influenzae Bronchitis:

Cite this brief

Drug Landscape (2026). Haemophilus Influenzae Bronchitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/haemophilus-influenzae-bronchitis. Accessed 2026-06-10.

Haemophilus Influenzae Bronchitis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing